Morgan Stanley and Medical Research News

This is selected news for Morgan Stanley and Medical Research, which are filed under Capital Firms and Healthcare Topics, respectively.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
11/25/2022 Laboratory Co. of America (NYSE:LH) PT Lowered to $305.00
... price objective would indicate a potential upside of 28.00% from the stock's current price. Other equities analysts also recently issued reports about the stock. Morgan Stanley dropped their target price on shares of Laboratory Co. of America from $300.00 to $290.00 and set an ‚Auoverweight‚Au rating for the ...
defenseworld.net
11/24/2022 Laboratory Co. of America (NYSE:LH) Given New $305.00 Price Target at Credit Suisse Group
Laboratory Co. of America (NYSE:LH ‚Ai Get Rating) had its target price decreased by Credit Suisse Group from $308.00 to $305.00 in a research note published on Wednesday morning, Stock Target Advisor reports. Credit Suisse Group currently has an outperform rating on the medical research company's stock. Other ...
baseballnewssource.com
11/24/2022 Thermo Fisher Scientific Inc. (NYSE:TMO) Forecasted to Earn Q4 2022 Earnings of $5.23 Per Share - The Cerbat Gem
... 5.58 EPS, Q2 2023 earnings at $5.56 EPS and FY2024 earnings at $25.25 EPS. Several other equities analysts have also weighed in on the stock. Morgan Stanley decreased their target price on shares of Thermo Fisher Scientific from $678.00 to $613.00 and set an ‚Auoverweight‚Au rating on the stock ...
thecerbatgem.com
11/23/2022 FY2024 EPS Estimates for Amgen Inc. Reduced by Analyst (NASDAQ:AMGN) - Ticker Report
Amgen Inc. ( NASDAQ:AMGN ‚Ai Get Rating ) ‚Ai Investment analysts at Zacks Research reduced their FY2024 earnings per share estimates for Amgen in a report released on Wednesday, November 16th. Zacks Research analyst K. Shah now anticipates that the medical research company will earn $18.30 per share for the year ...
Ticker Report
11/23/2022 Laboratory Co. of America (NYSE:LH) Price Target Cut to $305.00 by Analysts at Credit Suisse Group
... in on LH. William Blair reissued an ‚Auoutperform‚Au rating on shares of Laboratory Co. of America in a research report on Thursday, October 27th. Morgan Stanley lowered their target price on shares of Laboratory Co. of America from $300.00 to $290.00 and set an ‚Auoverweight‚Au rating for the ...
theenterpriseleader.com
11/21/2022 Amgen (NASDAQ:AMGN) Coverage Initiated at Credit Suisse Group
Credit Suisse Group initiated coverage on shares of Amgen ( NASDAQ:AMGN ‚Ai Get Rating ) in a report published on Thursday, MarketBeat.com reports. The brokerage issued an underperform rating and a $240.00 price target on the medical research company's stock. A number of other brokerages also recently issued reports on ...
zolmax.com
11/21/2022 Amgen (NASDAQ:AMGN) Coverage Initiated at Credit Suisse Group
... on Friday, November 4th. TheStreet raised shares of Amgen from a c+ rating to a b rating in a research note on Monday, August 15th. Morgan Stanley lifted their target price on shares of Amgen from $279.00 to $282.00 and gave the stock an overweight rating in a research note ...
baseballnewssource.com
11/21/2022 Quest Diagnostics (NYSE:DGX) Lowered to Sell at Citigroup
Citigroup downgraded shares of Quest Diagnostics (NYSE:DGX ‚Ai Get Rating) from a neutral rating to a sell rating in a report published on Thursday, MarketBeat reports. They currently have $125.00 price target on the medical research company's stock, down from their prior price target of $145.00. Other analysts ...
etfdailynews.com
11/21/2022 Quest Diagnostics (NYSE:DGX) Lowered to Sell at Citigroup
... research report on Friday, October 21st. William Blair reissued an outperform rating on shares of Quest Diagnostics in a research report on Thursday, October 20th. Morgan Stanley boosted their target price on Quest Diagnostics from $142.00 to $146.00 and gave the company an equal weight rating in a research report ...
defenseworld.net
11/21/2022 IQVIA (NYSE:IQV) Lowered to “Neutral” at Citigroup
Citigroup cut shares of IQVIA (NYSE:IQV ‚Ai Get Rating) from a buy rating to a neutral rating in a research report sent to investors on Thursday, Marketbeat Ratings reports. They currently have $245.00 price target on the medical research company's stock, down from their prior price target of ...
etfdailynews.com
11/20/2022 Amgen (NASDAQ:AMGN) Research Coverage Started at Credit Suisse Group - Ticker Report
... target on shares of Amgen from $235.00 to $240.00 and gave the stock a sector perform rating in a research note on Friday, November 4th. Morgan Stanley boosted their price target on shares of Amgen from $279.00 to $282.00 and gave the stock an overweight rating in a research note ...
Ticker Report
11/20/2022 Quest Diagnostics (NYSE:DGX) Cut to “Sell” at Citigroup
Citigroup lowered shares of Quest Diagnostics ( NYSE:DGX ‚Ai Get Rating ) from a neutral rating to a sell rating in a report released on Thursday, Marketbeat.com reports. The brokerage currently has $125.00 price target on the medical research company's stock, down from their prior price target of $145.00. Several ...
modernreaders.com
11/20/2022 IQVIA (NYSE:IQV) Cut to Neutral at Citigroup - Dakota Financial News
... price on the medical research company's stock, down from their prior target price of $275.00. Several other analysts have also commented on the company. Morgan Stanley cut their price objective on IQVIA from $260.00 to $240.00 and set an overweight rating for the company in a report on Thursday ...
Dakota Financial News
11/20/2022 Quest Diagnostics (NYSE:DGX) Lowered to “Sell” at Citigroup - Dakota Financial News
Citigroup cut shares of Quest Diagnostics ( NYSE:DGX ‚Ai Get Rating ) from a neutral rating to a sell rating in a report released on Thursday morning, Marketbeat reports. They currently have $125.00 target price on the medical research company's stock, down from their previous target price of $145.00. A ...
Dakota Financial News
11/20/2022 IQVIA (NYSE:IQV) Cut to Neutral at Citigroup
... price on the medical research company's stock, down from their prior target price of $275.00. Several other analysts have also commented on the company. Morgan Stanley cut their price objective on IQVIA from $260.00 to $240.00 and set an overweight rating for the company in a report on Thursday ...
American Banking News
11/19/2022 Citigroup Downgrades Quest Diagnostics (NYSE:DGX) to Sell - Ticker Report
Quest Diagnostics ( NYSE:DGX ‚Ai Get Rating ) was downgraded by Citigroup from a ‚Auneutral‚Au rating to a ‚Ausell‚Au rating in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. They currently have a $125.00 price target on the medical research company's stock, down ...
Ticker Report
11/19/2022 Citigroup Downgrades IQVIA (NYSE:IQV) to Neutral - Ticker Report
... July 22nd. Deutsche Bank Aktiengesellschaft reduced their price target on shares of IQVIA from $290.00 to $270.00 in a research report on Tuesday, October 18th. Morgan Stanley reduced their price target on shares of IQVIA from $260.00 to $240.00 and set an ‚Auoverweight‚Au rating on the stock in a ...
Ticker Report
11/19/2022 FY2022 EPS Estimates for Charles River Laboratories International, Inc. Raised by Zacks Research (NYSE:CRL)
... share estimates for Charles River Laboratories International in a research report issued on Wednesday, November 16th. Zacks Research analyst U. Biswas now anticipates that the medical research company will post earnings per share of $10.88 for the year, up from their previous forecast of $10.73. The consensus estimate for Charles ...
defenseworld.net
11/18/2022 Piper Sandler Lowers Heska (NASDAQ:HSKA) Price Target to $165.00 - Stock Observer
... firm currently has an overweight rating on the medical research company's stock. Several other equities research analysts have also recently issued reports on HSKA. Morgan Stanley decreased their price objective on shares of Heska from $149.00 to $135.00 and set an equal weight rating for the company in a ...
thestockobserver.com
11/18/2022 FY2022 EPS Estimates for Charles River Laboratories International, Inc. Boosted by Analyst (NYSE:CRL)
... River Laboratories International in a research report issued to clients and investors on Wednesday, November 16th. Zacks Research analyst U. Biswas now anticipates that the medical research company will post earnings of $10.88 per share for the year, up from their prior forecast of $10.73. The consensus estimate for Charles ...
American Banking News
11/18/2022 Amgen (NASDAQ:AMGN) Research Coverage Started at Credit Suisse Group - The Cerbat Gem
... Robert W. Baird reaffirmed an underperform rating and set a $185.00 price objective on shares of Amgen in a research report on Tuesday, September 13th. Morgan Stanley lifted their target price on Amgen from $279.00 to $282.00 and gave the stock an overweight rating in a report on Friday, November ...
thecerbatgem.com
11/18/2022 Amgen (NASDAQ:AMGN) Coverage Initiated by Analysts at Credit Suisse Group - Financial News Live
Credit Suisse Group began coverage on shares of Amgen (NASDAQ:AMGN ‚Ai Get Rating) in a report issued on Thursday morning, MarketBeat reports. The brokerage issued an underperform rating and a $240.00 target price on the medical research company's stock. AMGN has been the topic of a number of ...
finnewslive.com
11/18/2022 IQVIA (NYSE:IQV) Lowered to “Neutral” at Citigroup - Transcript Daily
... a report on Thursday, November 10th. Guggenheim raised their target price on shares of IQVIA to $249.00 in a report on Thursday, October 27th. Finally, Morgan Stanley dropped their price target on shares of IQVIA from $260.00 to $240.00 and set an overweight rating on the stock in a research ...
transcriptdaily.com
11/18/2022 Quest Diagnostics (NYSE:DGX) Cut to “Sell” at Citigroup - Slater Sentinel
Citigroup lowered shares of Quest Diagnostics ( NYSE:DGX ‚Ai Get Rating ) from a neutral rating to a sell rating in a research note released on Thursday morning, MarketBeat Ratings reports. Citigroup currently has $125.00 price target on the medical research company's stock, down from their prior price target of ...
slatersentinel.com
11/18/2022 Piper Sandler Lowers Heska (NASDAQ:HSKA) Price Target to $165.00
... decreased their price objective on Heska from $155.00 to $119.00 and set a buy rating for the company in a report on Wednesday, November 9th. Morgan Stanley cut their target price on Heska from $149.00 to $135.00 and set an equal weight rating on the stock in a research report ...
The Markets Daily